Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial.
Verheyen N, Fahrleitner-Pammer A, Belyavskiy E, Gruebler MR, Dimai HP, Amrein K, Ablasser K, Martensen J, Catena C, Pieske-Kraigher E, Colantonio C, Voelkl J, Lang F, Alesutan I, Meinitzer A, März W, Brussee H, Pieske B, Pilz S, Tomaschitz A. Verheyen N, et al. Among authors: ablasser k. PLoS One. 2017 Apr 13;12(4):e0173799. doi: 10.1371/journal.pone.0173799. eCollection 2017. PLoS One. 2017. PMID: 28406904 Free PMC article. Clinical Trial.
Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study.
Grübler MR, Kienreich K, Gaksch M, Verheyen N, Fahrleitner-Pammer A, Schmid J, Grogorenz J, Ablasser K, Pieske B, Tomaschitz A, Pilz S. Grübler MR, et al. Among authors: ablasser k. J Clin Hypertens (Greenwich). 2014 Apr;16(4):289-94. doi: 10.1111/jch.12274. Epub 2014 Mar 26. J Clin Hypertens (Greenwich). 2014. PMID: 24666971 Free PMC article.
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial.
Verheyen N, Meinitzer A, Grübler MR, Ablasser K, Kolesnik E, Fahrleitner-Pammer A, Belyavskiy E, Trummer C, Schwetz V, Pieske-Kraigher E, Voelkl J, Alesutan I, Catena C, Sechi LA, Brussee H, Lewinski DV, März W, Pieske B, Pilz S, Tomaschitz A. Verheyen N, et al. Among authors: ablasser k. Clin Chem Lab Med. 2017 Jun 27;55(7):1034-1042. doi: 10.1515/cclm-2016-1159. Clin Chem Lab Med. 2017. PMID: 28432842 Clinical Trial.
Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseases.
Haudum CW, Kolesnik E, Colantonio C, Mursic I, Url-Michitsch M, Tomaschitz A, Glantschnig T, Hutz B, Lind A, Schweighofer N, Reiter C, Ablasser K, Wallner M, Tripolt NJ, Pieske-Kraigher E, Madl T, Springer A, Seidel G, Wedrich A, Zirlik A, Krahn T, Stauber R, Pieske B, Pieber TR, Verheyen N, Obermayer-Pietsch B, Schmidt A. Haudum CW, et al. Among authors: ablasser k. BMJ Open. 2022 Apr 7;12(4):e058890. doi: 10.1136/bmjopen-2021-058890. BMJ Open. 2022. PMID: 35393327 Free PMC article.
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort.
Santner V, Riepl HS, Posch F, Wallner M, Rainer PP, Ablasser K, Kolesnik E, Hoeller V, Zach D, Schwegel N, Kreuzer P, Lueger A, Petutschnigg J, Pieske B, Zirlik A, Edelmann F, Verheyen N. Santner V, et al. Among authors: ablasser k. Eur J Intern Med. 2023 Dec;118:73-81. doi: 10.1016/j.ejim.2023.07.027. Epub 2023 Jul 28. Eur J Intern Med. 2023. PMID: 37517939 Free article.
Outcomes of ECLS-SHOCK Eligibility Criteria Applied to a Real-World Cohort.
von Lewinski D, Herold L, Bachl E, Bugger H, Glantschnig T, Kolesnik E, Verheyen N, Benedikt M, Wallner M, von Lewinski F, Schmidt A, Harb S, Ablasser K, Sacherer M, Scherr D, Manninger-Wünscher M, Pätzold S, Gollmer J, Zirlik A, Toth GG. von Lewinski D, et al. Among authors: ablasser k. J Clin Med. 2023 Nov 8;12(22):6988. doi: 10.3390/jcm12226988. J Clin Med. 2023. PMID: 38002602 Free PMC article.
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.
Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D. Wallner M, et al. Among authors: ablasser k. J Mol Cell Cardiol. 2015 Dec;89(Pt B):365-75. doi: 10.1016/j.yjmcc.2015.09.018. Epub 2015 Oct 1. J Mol Cell Cardiol. 2015. PMID: 26432951
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, Siller-Matula J, Weidinger F, Zechner PM, von Lewinski D, Sourij H; EMMY study group. Tripolt NJ, et al. Among authors: ablasser k. Am Heart J. 2020 Mar;221:39-47. doi: 10.1016/j.ahj.2019.12.004. Epub 2019 Dec 12. Am Heart J. 2020. PMID: 31901799
Indications and Outcome in Patients Undergoing Left Atrial Appendage Closure-The Austrian LAAC Registry.
Zweiker D, Sieghartsleitner R, Fiedler L, Toth GG, Luha O, Stix G, Gabriel H, Vock P, Lileg B, Strouhal A, Delle-Karth G, Pfeffer M, Aichinger J, Tkalec W, Steinwender C, Sihorsch K, Binder RK, Rammer M, Barbieri F, Mueller S, Verheyen N, Ablasser K, Zirlik A, Scherr D. Zweiker D, et al. Among authors: ablasser k. J Clin Med. 2020 Oct 13;9(10):3274. doi: 10.3390/jcm9103274. J Clin Med. 2020. PMID: 33066034 Free PMC article.
44 results